RedHill Biopharma is a specialty biopharmaceutical company headquartered in Tel Aviv, Israel, that develops and commercializes treatments primarily targeting gastrointestinal and infectious diseases. The company's marketed products include Talicia for H. pylori infection in adults and Aemcolo for travelers' diarrhea in adults. These represent the core of its current revenue-generating business.
The company maintains a pipeline of five therapeutic candidates in clinical development across multiple indications. These candidates include opaganib (evaluated for severe COVID-19 pneumonia, prostate cancer, and radiation protection applications), RHB-107/upamostat (for COVID-19 and advanced cholangiocarcinoma), RHB-104 (for Crohn's disease), RHB-102/Bekinda (for acute gastroenteritis and gastritis among other gastrointestinal conditions), and RHB-204 (in Phase 3 testing for pulmonary Mycobacterium avium complex disease).
RedHill operates with a small workforce of 35 full-time employees and is listed on Nasdaq. The company was incorporated in 2009 and maintains operations primarily from its Israeli headquarters, with its development activities focused on addressing therapeutic gaps in gastrointestinal and infectious disease treatment categories.
No 10-K filings found.